Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | KAT8 | Q9H7Z6 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2377443 | 1.00 | BTK (0.64) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL15909157 | 1.00 | BTK (0.64) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL21027650 | 1.00 | BTK (0.64) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL941984 | 1.00 | BTK (0.64) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL25524123 | 1.00 | BTK (0.64) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL25319683 | 1.00 | BTK (0.64) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL14084772 | 0.97 | BTK (0.60) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL3906349 | 0.91 | BTK (0.55) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL19156343 | 0.91 | BTK (0.55) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL3903151 | 0.91 | BTK (0.55) | BTKKMT2AL3MBTL1EPHX1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312557-A1 | P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2023-10-05 | — | — | US | disclosed |
| WO-2023091726-A1 | INHIBITORS OF CYCLIN‑DEPENDENT KINASE 12 (CDK12) | SYROS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023091726-A1 | INHIBITORS OF CYCLIN‑DEPENDENT KINASE 12 (CDK12) | SYROS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-11053221-B2 | Substituted pyrimidines for inhibiting embryonic leucine zipper kinase activity | ARRIEN PHARMACEUTICALS LLC (US) | 2021-07-06 | — | — | US | disclosed |
| EP-3057956-B1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-10906889-B2 | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10865206-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200131154-A1 | PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | ARRIEN PHARMACEUTICALS LLC | 2020-04-30 | — | — | US | disclosed |
| US-20190337940-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-11-07 | — | — | US | disclosed |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-07-26 | — | — | US | disclosed |
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-11-16 | — | — | US | disclosed |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-29 | — | — | US | disclosed |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2016-09-15 | — | — | US | disclosed |
| WO-2016058544-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
| WO-2015154039-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015058140-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20110009435-A1 | HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2170843-A1 | HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | Pfizer Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008149191-A1 | HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053221-B2 | Substituted pyrimidines for inhibiting embryonic leucine zipper kinase activity | MELK, TK1, DCK | BTK 2370/4885KMT2A 962/4885L3MBTL1 4/4885 |
| US-20230312557-A1 | P2X3 MODULATORS | P2RX3, P2RX2, P2RX6 | BTK 3126/4885KMT2A 4284/4885L3MBTL1 4348/4885 |
| US-10906889-B2 | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK13, CDK3, CDK12 | BTK 1478/4885KMT2A 1382/4885L3MBTL1 1537/4885 |
| US-20190337940-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | BTK 1407/4885KMT2A 1231/4885L3MBTL1 2232/4885 |
| US-20110009435-A1 | HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CNR2, CYP2C9, CYP2C8 | BTK 1877/4885KMT2A 1984/4885L3MBTL1 4880/4885 |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | BTK 1779/4885KMT2A 1283/4885L3MBTL1 2201/4885 |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK13, CDK3, CDK12 | BTK 1478/4885KMT2A 1382/4885L3MBTL1 1537/4885 |
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | BTK 1407/4885KMT2A 1231/4885L3MBTL1 2232/4885 |
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | BTK 1407/4885KMT2A 1231/4885L3MBTL1 2232/4885 |
| US-20200131154-A1 | PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | PAICS, MCL1, TP53 | BTK 1354/4885KMT2A 784/4885L3MBTL1 276/4885 |
| US-10865206-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | BTK 1407/4885KMT2A 1231/4885L3MBTL1 2232/4885 |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | BTK 1779/4885KMT2A 1283/4885L3MBTL1 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.